Abstract | BACKGROUND:
Trastuzumab, a humanized anti-HER2 antibody, increases the clinical benefit of first-line chemotherapy in patients with metastatic breast cancers that overexpress HER2. We characterized interactions between trastuzumab and chemotherapeutic agents commonly used in the treatment of breast cancer. METHODS: Multiple drug effect/combination index isobologram analysis was used to study the efficacy of chemotherapeutic drug plus trastuzumab combinations tested against four HER2-overexpressing breast cancer cell lines (SK-BR-3, BT-474, MDA-MB-361, and MDA-MB-453). Combination index values were derived from parameters of the median effect plots, and statistical tests were used to determine whether the mean combination index values at multiple effect levels were statistically significantly different from a combination index value of 1.0. Values less than 1.0 indicate synergistic interactions, values greater than 1.0 indicate antagonistic interactions, and values equal to 1.0 indicate additive interactions. RESULTS: CONCLUSION:
|
Authors | Mark D Pegram, Gottfried E Konecny, Carminda O'Callaghan, Malgorzata Beryt, Richard Pietras, Dennis J Slamon |
Journal | Journal of the National Cancer Institute
(J Natl Cancer Inst)
Vol. 96
Issue 10
Pg. 739-49
(May 19 2004)
ISSN: 1460-2105 [Electronic] United States |
PMID | 15150302
(Publication Type: Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- DNA, Neoplasm
- Guanine Nucleotide Exchange Factors
- MCF2 protein, human
- Mcf2 protein, mouse
- Proto-Oncogene Proteins
- Taxoids
- Floxuridine
- Deoxycytidine
- Docetaxel
- 4-hydroxycyclophosphamide
- Epirubicin
- Vinblastine
- Doxorubicin
- Cyclophosphamide
- Carboplatin
- Receptor, ErbB-2
- Trastuzumab
- Paclitaxel
- Vinorelbine
- doxifluridine
- Gemcitabine
|
Topics |
- Animals
- Antibodies, Monoclonal
(pharmacology)
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols
(pharmacology)
- Breast Neoplasms
(drug therapy, metabolism)
- Carboplatin
(pharmacology)
- Cell Line, Tumor
- Cell Survival
(drug effects)
- Cyclophosphamide
(analogs & derivatives, pharmacology)
- DNA, Neoplasm
(drug effects)
- Deoxycytidine
(analogs & derivatives, pharmacology)
- Disease Models, Animal
- Docetaxel
- Doxorubicin
(pharmacology)
- Drug Synergism
- Enzyme-Linked Immunosorbent Assay
- Epirubicin
(pharmacology)
- Female
- Floxuridine
(pharmacology)
- Gene Expression Regulation, Neoplastic
(drug effects)
- Guanine Nucleotide Exchange Factors
- Humans
- Mice
- Mice, Nude
- Neoplastic Stem Cells
(drug effects)
- Paclitaxel
(pharmacology)
- Proto-Oncogene Proteins
(drug effects)
- Receptor, ErbB-2
(drug effects, metabolism)
- Taxoids
(pharmacology)
- Transplantation, Heterologous
- Trastuzumab
- Tumor Stem Cell Assay
- Up-Regulation
- Vinblastine
(analogs & derivatives, pharmacology)
- Vinorelbine
- Gemcitabine
|